Citations

Showing 10 of 108104 citations.

CSIG-05. PI3K INHIBITORS PX-866 AND BEZ235 DIFFERENTIALLY MODULATE AUTOPHAGY IN GBM
Harder, Bryan , Sereduk, Christopher, Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi43-vi44

10.1093/neuonc/noy148.171 Get It

GENE-11. SMALL TERMINAL ALTERATIONS AND ALTERNATIVE LENGTHENING OF TELOMERES ARE A FEATURE OF IDH-MUTANT, 1p/19q NON-CODELETED GLIOMAS
Yamada, Seiji , Jacobs, Joshua , Decker, Paul A. , Kosel, Matt, Caron, Alissa, Halder, Chandralekha, Ruiz, Vanessa , Kipp, Benjamin R. , Voss, Jesse S. , Vaubel, Rachel, Jenkins, Robert B. , Brown, Desmond , Praska, Corinne , Kollmeyer, Thomas M. , Decker, Paul A. , Kosel, Matthew , Giannini, Caterina

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi105-vi105

10.1093/neuonc/noy148.438 Get It

PATH-12. CHARACTERISTICS OF GIANT CELL MORPHOLOGY IN LONG-TERM SURVIVORS OF GLIOBLASTOMA: CONSIDERATION OF SEX DIFFERENCES
Johnston, Sandra K. , Bayless, Spencer, Mrugala, Maciej , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi160-vi160

10.1093/neuonc/noy148.668 Get It

TMIC-36. LOCAL TISSUE BIOMARKERS OF RESPONSE TO THERAPY FOR GLIOBLASTOMA
Olson, Ian , Jacobs, Joshua , Rajani, Karishma , Macura, Slobodan , Sarkaria, Jann N. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi264-vi264

10.1093/neuonc/noy148.1095 Get It

NIMG-57. IMAGING FEATURES OF POLYMORPHOUS LOWGRADE NEUROEPITHELIAL TUMOR OF THE YOUNG (PLNTY)
Johnson, Derek R. , Giannini, Caterina , Kaufmann, Timothy J. , Morris, Jonathan M.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi189-vi189

10.1093/neuonc/noy148.783 Get It

DDIS-25. TARGETING GLIOBLASTOMA HETEROGENEITY WITH miR-34a
Khan, Muhammad Babar , Ruggieri, Rosamaria, MacDiarmid, Jennifer A. , Brahmbhatt, Himanshu , Boockvar, John A. , Symons, Marc , Tran, Nhan L. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi74-vi74

10.1093/neuonc/noy148.304 Get It

STEM-08. MODULATION OF RADIATION-INDUCED MESENCHYMAL STEM CELL MIGRATION IN GLIOBLASTOMA
Harrell, Anna , Mondal, Sujan Kumar , Quiñones‐Hinojosa, Alfredo , Ruiz-García, Henry , Sarabia-Estrada, Rachel , Alvarado-Estrada, Keila , Trifiletti, Daniel M.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi245-vi245

10.1093/neuonc/noy148.1015 Get It

ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
Pafundi, Deanna, Anderson, S. Keith , Zakhary, Mark J. , Tseung, Hok Seum Wan Chan, Lowe, Val J. , Yan, Elizabeth , Kizilbash, Sani H. , Uhm, Joon H. , Hu, Leland , Brown, Paul D. , Buckner, Jan C. , Brinkmann, Debra H. , Kizilbash, Sani H , Laack, Nadia N. , Hunt, Christopher H. , Kaufmann, Timothy J. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi13-vi13

10.1093/neuonc/noy148.046 Get It

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
Fisher, Barbara, Macdonald, David , Chakravarti, Arnab , Lesser, Glenn J. , Fox, Sherry, Coons, Stephen W., Rogers, Leland , Werner‐Wasik, Maria, Doyle, Thomas J. , Bahary, Jean-Paul , Fiveash, John B. , Bovi, Joseph , Howard, Steven , Yu, Michael , D’Souza, David , Roach, Mack , Kwok, Young , Wahl, Daniel , Stasser, John, Won, Minhee , Zhang, Peixin, Fox, Sherry, Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi11-vi11

10.1093/neuonc/noy148.039 Get It

Identifying high‐cost episodes in lower extremity joint replacement
Philpot, Lindsey M. , Swanson, Kristi M. , Inselman, Jonathan , Schoellkopf, William J., Naessens, James M. , Gladders, Barbara , Shah, Nilay D. , Ebbert, Jon O. , Borah, Bijan J. , Peterson, Stephanie, Ebbert, Jon O , Philpot, Lindsey M , Peterson, Stephanie

Mayo Clinic

Health Services Research | November 5, 2018 | Volume: 54 | Issue: 1 | Pages: 117-127

10.1111/1475-6773.13078 | PMID 30394529 Get It

ObjectivesTo evaluate the ability of claims‐based risk adjustment and incremental components of clinical data to identify 90‐day episode costs among lower extremity joint replacement (LEJR) patients according to the Centers for Medicare & Medicaid Services (CMS) Comprehensive Care for Joint Replacement (CJR) program provisions.Data SourcesMedicare fee‐for‐service (FFS) data for qualifying CJR episodes in the United States, and FFS data linked with clinical data from CJR‐qualifying LEJR episodes performed at High Value Healthcare Collaborative (HVHC) and Mayo Clinic in 2013. HVHC and Mayo Clinic populations are subsets of the total FFS population to assess the additive value of additional pieces of clinical data in correctly assigning patients to cost groups.Study DesignMultivariable logistic models identified high‐cost episodes.Data Collection/Extraction MethodsClinical data from participating health care systems merged with Medicare FFS data.Principal FindingsOur three populations consisted of 363 621 patients in the CMS population, 4881 in the HVHC population, and 918 in the Mayo population. When modeling per CJR specifications, we observed low to moderate model performance (CMS C‐Stat = 0.714; HVHC C‐Stat = 0.628; Mayo C‐Stat = 0.587). Adding CMS‐HCC categories improved identification of patients in the top 20% of episode costs (CMS C‐Stat = 0.758, HVHC C‐Stat = 0.692, Mayo C‐Stat = 0.677). Clinical variables, particularly functional status in the population for which this was available (Mayo C‐Stat = 0.783), improved ability to identify patients within cost groups.ConclusionsPolicy makers could use these findings to improve payment adjustments for bundled LEJR procedures and in consideration of new data elements for reimbursement.